This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Smith ER , Cai KQ , Smedberg JL , Ribeiro MM , Rula ME , Slater C , Godwin AK , Xu XX
Nuclear Entry of Activated MAPK Is Restricted in Primary Ovarian and Mammary Epithelial Cells
Plos One. 2010 Feb;5(2)
PMID: ISI:000274654700022 PMCID: PMC2823791
AbstractBackground: The MAPK/ERK1/2 serine kinases are primary mediators of the Ras mitogenic signaling pathway. Phosphorylation by MEK activates MAPK/ERK in the cytoplasm, and phospho-ERK is thought to enter the nucleus readily to modulate transcription. Principal Findings: Here, however, we observe that in primary cultures of breast and ovarian epithelial cells, phosphorylation and activation of ERK1/2 are disassociated from nuclear translocalization and transcription of downstream targets, such as c-Fos, suggesting that nuclear translocation is limited in primary cells. Accordingly, in import assays in vitro, primary cells showed a lower import activity for ERK1/2 than cancer cells, in which activated MAPK readily translocated into the nucleus and activated c-Fos expression. Primary cells express lower levels of nuclear pore complex proteins and the nuclear transport factors, importin B1 and importin 7, which may explain the limiting ERK1/2 import found in primary cells. Additionally, reduction in expression of nucleoporin 153 by siRNA targeting reduced ERK1/2 nuclear activity in cancer cells. Conclusion: ERK1/2 activation is dissociated from nuclear entry, which is a rate limiting step in primary cells and in vivo, and the restriction of nuclear entry is disrupted in transformed cells by the increased expression of nuclear pores and/or nuclear transport factors.
NotesSmith, Elizabeth R. Cai, Kathy Qi Smedberg, Jennifer L. Ribeiro, Melina M. Rula, Malgorzata E. Slater, Carolyn Godwin, Andrew K. Xu, Xiang-Xi National Cancer Institute [R01CA099471, R01CA79716, R01CA75389]; Marsha Rivkin Ovarian Cancer Research Center and DOD Ovarian Concept [W81XWH-07-1-0303] This work was supported by National Cancer Institute grants R01CA099471, R01CA79716, and R01CA75389 (to X-XX). E. R. S. received support from the Marsha Rivkin Ovarian Cancer Research Center and DOD Ovarian Concept W81XWH-07-1-0303. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. 55 Public library science; 185 berry st, ste 1300, san francisco, ca 94107 usa 557fj